Merck Aktie

Merck für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A0YD8Q / ISIN: US58933Y1055

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
13.09.2022 13:24:07

Merck: KEYTRUDA Approved In Canada For Adjuvant Treatment Of Patients With Stage IIB Or IIC Melanoma

(RTTNews) - Merck (MRK) announced that Health Canada has granted approval for KEYTRUDA, the company's anti-PD-1 therapy, for the adjuvant treatment of adult and pediatric patients with stage IIB or IIC melanoma following complete resection. The approval is based on the results from the phase 3 KEYNOTE-716 trial.

KEYTRUDA was first approved in Canada in 2015. It currently has indications in several disease areas, including advanced renal cell carcinoma, bladder cancer, non-small cell lung carcinoma, primary mediastinal B-cell lymphoma, classical Hodgkin lymphoma, colorectal cancer, endometrial carcinoma, esophageal cancer, triple-negative breast cancer, melanoma, and head and neck squamous cell carcinoma.

For More Such Health News, visit rttnews.com.

Analysen zu Merck Co.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Merck Co. 67,60 -2,73% Merck Co.